# Biogen Secures Approval for New Form of Alzheimer Drug Subcutaneous version of Leqembi receives FDA approval. - **Source:** [Breaking News on Seeking Alpha](https://brifing.si/source/9a596115-e1cc-45e7-b5ba-070be9ea2998) - **Published:** 2026-07-13 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/47da49b6-06f7-4686-862c-afff767bf6da ## New Form Approved Biogen and Eisai have secured FDA approval for a subcutaneous version of their Alzheimer drug, Leqembi. This new form can be used for both initiation and maintenance doses. ## Home Use Possibility Leqembi Iqlik is designed for home use, allowing patients to administer the drug themselves. This makes the treatment process easier and more accessible. ## Treatment Convenience The subcutaneous administration method offers a less invasive treatment option, providing a significant advantage for Alzheimer patients. ## FDA Approval FDA's approval marks a significant milestone for Biogen and Eisai. The new form of the drug could quickly gain a foothold in the market. ## Market Impact The launch of Leqembi's new version could positively impact Biogen and Eisai's stocks, representing a financial success for the companies. ## Future Expectations The success of Leqembi Iqlik could usher in a new era in Alzheimer treatment, offering hope for both patients and the healthcare sector. ## Sources covering this story - https://seekingalpha.com/news/4613404-biogen-nabs-approval-subcutaneous-version-leqembi-initiation-dose?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._